Symetis and Boston Scientific reach USD 435 million purchase agreement
Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment; Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease; Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions; Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted.